Browse the evidence

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce liver fat content in patients with NAFLD, as assessed by MRI-based techniques.

SGLT2 inhibitors like empagliflozin or dapagliflozin reduce liver fat in people with type 2 diabetes and fatty liver. They are oral medications taken daily. They can increase the risk of genital infections, so good hygiene is important. They also help with weight and blood sugar.

Physical exercise provides cardiovascular and mental health benefits independent of weight loss, justifying its inclusion in obesity treatment even when pharmacological weight loss is significant.

Even if your medication helps you lose weight, keep exercising. It protects your heart and mood in ways that weight loss alone might not. Focus on brisk walking and basic strength exercises rather than intense workouts.

Industrial trans fats are harmful and should be avoided, while natural trans fats (from ruminants) are beneficial and may protect against heart disease.

Avoid processed foods with 'partially hydrogenated oils' (industrial trans fats). However, do not avoid natural trans fats found in butter and meat from grass-fed animals, as they may actually protect your heart.

Gastric bypass results in large and long-lasting weight loss (25-27% total body weight loss at 12-15 years) and remission of obesity-related conditions, making it suitable for patients with BMI 35-50 kg/m2, especially with type 2 diabetes or reflux.

Gastric bypass is a highly effective surgical option for patients with BMI 35-50, especially those with type 2 diabetes or reflux. It leads to large, long-lasting weight loss (25-27% at 12-15 years) and remission of obesity-related conditions.

Tirzepatide (15 mg) produces a greater improvement in insulin sensitivity per unit of weight loss compared to semaglutide (1 mg) in patients with type 2 diabetes, suggesting mechanisms beyond simple adiposity reduction.

If you are treating type 2 diabetes with GLP-1 based therapies, tirzepatide (15 mg) appears to offer superior improvements in how your body uses insulin for every pound lost, compared to semaglutide (1 mg). This suggests tirzepatide works through additional hormonal pathways (GIP/GLP-1) beyond just reducing fat mass. For patients prioritizing metabolic health improvements alongside weight loss, this distinction may be clinically relevant.

GLP-1 receptor agonists (e.g., Liraglutide) reduce appetite and improve glucose tolerance by stimulating anorexigenic POMC/CART neurons and suppressing orexigenic AgRP/NPY neurons via cAMP and GABA-dependent signaling pathways.

GLP-1 based therapies work by targeting the brain's hunger centers (POMC/CART) to reduce appetite and improve blood sugar control. This suggests that obesity management can involve pharmacological support of natural hormonal signals, rather than relying solely on behavioral changes.

Higher circulating levels of long-chain omega-3 fatty acids (EPA and DHA) are inversely associated with the incidence of cardiovascular disease (CVD), whereas omega-6 linoleic acid (LA) and plant-derived alpha-linolenic acid (ALA) show no significant protective association with CVD incidence.

Focus on increasing long-chain omega-3s (EPA/DHA) from seafood sources rather than relying solely on plant-based omega-3s (ALA) or omega-6 oils for cardiovascular prevention. Higher blood levels of EPA and DHA are strongly linked to a significantly lower risk of heart disease and stroke.

Increased adiposity (measured by BMI) causes an increased risk of incident heart failure and ischaemic stroke, as demonstrated by Mendelian randomization analysis using a genetic risk score.

Maintaining a healthy body weight is a direct way to lower your risk of heart failure and stroke. This isn't just about appearance; excess weight actively causes these conditions. Focus on sustainable lifestyle changes to manage weight, as this directly impacts your cardiovascular health.

Regression from prediabetes to normal glucose regulation (NGR) is associated with a significant reduction in estimated 10-year cardiovascular disease (CVD) risk.

If you have prediabetes, working to return your blood sugar levels to the normal range (NGR) is associated with a lower estimated risk of cardiovascular disease over 10 years compared to staying in the prediabetes state. This suggests that interventions achieving NGR, whether through lifestyle changes or medication, may offer cardiovascular benefits.

Fermented dairy products (cheese, yogurt) and probiotics are associated with a lower risk of cardiovascular disease (CVD) and type 2 diabetes, independent of saturated fat content, whereas non-fermented low-fat milk may be associated with higher diabetes risk.

Prioritize fermented dairy products like cheese and yogurt over non-fermented low-fat milk for metabolic health. These foods are associated with a lower risk of cardiovascular disease and type 2 diabetes. The fermentation process and specific fatty acid profiles in dairy appear to offer protective benefits that contradict the general fear of saturated fats.

Testosterone therapy in transgender men leads to increased lean mass and visceral adiposity, while estrogen therapy in transgender women leads to decreased lean mass and increased fat mass, confirming the causal role of sex steroids in body composition.

If you are undergoing gender-affirming hormone therapy, expect your body composition to shift towards your new hormonal profile. Trans men will likely gain muscle and visceral fat; trans women will likely lose muscle and gain subcutaneous fat. This is a direct result of the hormones, not lifestyle failure.

Menopause triggers a shift in fat distribution from protective subcutaneous tissue to harmful visceral adipose tissue due to declining estrogen levels, increasing the risk of metabolic disease.

As you approach menopause, your body will naturally start storing more fat around your organs (visceral) rather than your hips and thighs. This increases metabolic risk. Hormone replacement therapy can partially reverse this shift, but lifestyle management of visceral fat becomes critical.

GLP-1 receptor agonists (specifically liraglutide 3.0 mg) produce clinically significant weight loss in overweight or obese individuals through reduced appetite and energy intake, rather than increased energy expenditure.

If you are overweight or obese, GLP-1 receptor agonists like liraglutide (3.0 mg daily) are a clinically proven tool for weight loss. They work by making you feel fuller and reducing your desire to eat, not by speeding up your metabolism. Treatment involves starting at a low dose and slowly increasing it to manage side effects. This intervention is most effective when combined with your usual lifestyle habits, though significant weight loss occurs even without strict diet changes in some studies.

Whey protein supplementation (Concentrate and Hydrolysate) increases skeletal muscle satellite cell counts compared to baseline, whereas soy and leucine do not, suggesting a potential mechanism for long-term adaptation despite no immediate hypertrophy benefit.

While whey, soy, and leucine all support similar muscle size gains in beginners, whey might offer a unique benefit by increasing satellite cells (muscle repair cells). This might not show up in 12 weeks, but could be beneficial for long-term training. If you prefer whey, this is a potential bonus, but it's not a requirement for growth.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is bidirectionally associated with the development and progression of cardiovascular, renal, and metabolic disorders, acting as both a driver and consequence of systemic cardiometabolic dysfunction.

If you have fatty liver (MASLD), it is not just a liver issue; it significantly increases your risk for heart disease, kidney disease, and diabetes. You need to manage your metabolic health (weight, blood sugar, blood pressure) comprehensively to protect your heart and kidneys, not just your liver.

SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone demonstrate benefits across multiple cardiometabolic conditions, improving clinical outcomes in patients with MASLD, CKD, and CVD.

Current medications like SGLT2 inhibitors, GLP-1 agonists, and finerenone are effective for treating multiple aspects of cardiometabolic disease simultaneously. Discuss these options with your doctor if you have liver, kidney, or heart issues.

Supplementing plant-based proteins (specifically soy or pea) with extra leucine or essential amino acids can equalize the muscle protein synthesis response to whey protein, but long-term supplementation with leucine alone does not increase muscle mass or strength in older adults.

Do not rely on leucine supplements alone to build muscle. While adding leucine to a small plant-protein meal can make it work as well as a larger animal-protein meal for immediate muscle signaling, taking leucine pills on top of your normal diet has not been shown to increase muscle mass or strength in older adults. Focus on eating enough total protein from whole foods or complete plant proteins instead.

Menopause triggers a shift in body composition toward increased visceral and perivascular fat and reduced fat-free mass, independent of modest total weight gain, driven by estrogen deficiency and elevated FSH.

Do not rely on the scale alone during menopause. Your risk is increasing even if your weight stays stable because you are losing muscle and gaining dangerous visceral fat. Measure your waist circumference and prioritize resistance training to preserve muscle mass.

Estrogen replacement therapy (ERT) and progestin therapy reduce BMI, waist circumference, fasting insulin, and the incidence of new diabetes compared to placebo.

If you are experiencing menopausal symptoms and metabolic risks, discuss Hormone Replacement Therapy (HRT) with your doctor. It may help lower your risk of developing type 2 diabetes and improve body composition, though you must weigh this against potential side effects.

Energy-restricted diets result in modest long-term weight loss (approx. 3% maintained at 5 years) and high relapse rates (>80%) due to compensatory metabolic adaptations including increased hunger hormones (ghrelin), decreased satiety hormones (leptin, GLP-1, PYY), and reduced energy expenditure.

Standard calorie restriction often fails long-term because your body fights back by increasing hunger hormones and lowering metabolism. To succeed, you must manage these biological responses, likely by prioritizing high protein intake to help suppress hunger hormones like ghrelin and preserve metabolic rate, rather than just cutting calories blindly.

Tirzepatide (5-15 mg once weekly) significantly reduces the risk of composite kidney endpoints (eGFR decline ≥40%, renal death, kidney failure, or new-onset macroalbuminuria) in patients with type 2 diabetes and high cardiovascular risk compared to insulin glargine.

If you have type 2 diabetes and are at high risk for heart or kidney problems, tirzepatide (a once-weekly injection) has been shown to significantly reduce the risk of serious kidney issues compared to insulin glargine. This benefit includes slowing the decline in kidney function and preventing the onset of severe protein in the urine. While there may be an initial, reversible drop in kidney function numbers, this is a sign of reduced stress on the kidneys. Always consult your doctor to see if this treatment is appropriate for your specific health profile.

BCAA supplementation activates anabolic signaling pathways (mTORC1) and improves hormonal profiles (testosterone/cortisol ratio) in the short term, but this does not translate to long-term muscle or strength gains if total protein intake is adequate.

BCAAs do trigger muscle-building signals in your body, but this doesn't mean you will gain muscle or strength. If you are eating enough protein from food, BCAAs add no value. Do not use them to try to 'boost' your muscle growth.

Time-restricted eating (TRE) improves metabolic health markers (insulin sensitivity, glucose control) independent of weight loss when the eating window is aligned with circadian rhythms (early/mid-TRE), whereas late or self-selected windows show little to no benefit.

If you want to try Time-Restricted Eating, start by shifting your eating window to the earlier part of the day (e.g., 8am to 4pm or 10am to 6pm) rather than skipping breakfast or eating late at night. Keep your food choices normal (ad libitum) but ensure you finish eating before 8pm. This alignment with your body's natural circadian rhythms is what drives metabolic improvements, independent of weight loss.

Liraglutide improves insulin sensitivity (measured by HOMA-IR, HOMA2, and Matsuda index) rapidly, within 2 weeks, independent of weight loss.

If you have obesity and prediabetes, liraglutide improves how your body handles insulin within two weeks, even before you lose significant weight. This is a direct drug effect, not just a result of dieting.